Literature DB >> 2528778

Drug inhibition indicates a single-site model of the 5-HT uptake site/antidepressant binding site in rat and human brain.

J O Marcusson1, A Andersson, I Bäckström.   

Abstract

Drug inhibition against [3H]paroxetine binding to rat cortex and human putamen was investigated in saturation experiments. The addition of 5-HT, imipramine, citalopram and clomipramine all produced changes in apparent binding affinity (Kd) without changes in the number of binding sites (Bmax). These data suggest that there is no heterogeneity of specific [3H]paroxetine binding, supporting a single site model of the 5-HT uptake site and antidepressant binding site.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2528778     DOI： 10.1007/bf00634446

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


  22 in total

1.  High- and low-affinity binding components for [3H]imipramine in rat cerebral cortex.

Authors:  P G Conway; D J Brunswick
Journal:  J Neurochem       Date:  1985-07       Impact factor: 5.372

2.  Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor.

Authors:  D R Thomas; D R Nelson; A M Johnson
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Differentiation of two components of specific [3H]imipramine binding in rat brain.

Authors:  P D Hrdina
Journal:  Eur J Pharmacol       Date:  1984-07-20       Impact factor: 4.432

4.  High- and low-affinity binding of [3H]imipramine in mouse cerebral cortex.

Authors:  M E Reith; H Sershen; D Allen; A Lajtha
Journal:  J Neurochem       Date:  1983-02       Impact factor: 5.372

5.  Association of [3H]-imipramine and [3H]-paroxetine binding with the 5HT transporter in brain and platelets: relevance to studies in depression.

Authors:  S Z Langer; A M Galzin; M F Poirier; H Loo; D Sechter; E Zarifian
Journal:  J Recept Res       Date:  1987

6.  High and low affinity [3H]imipramine binding sites in control and parkinsonian brains.

Authors:  R Cash; R Raisman; A Ploska; Y Agid
Journal:  Eur J Pharmacol       Date:  1985-10-29       Impact factor: 4.432

7.  Aminergic systems in Alzheimer's disease and Parkinson's disease.

Authors:  R J D'Amato; R M Zweig; P J Whitehouse; G L Wenk; H S Singer; R Mayeux; D L Price; S H Snyder
Journal:  Ann Neurol       Date:  1987-08       Impact factor: 10.422

8.  Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine.

Authors:  R J D'Amato; B L Largent; A M Snowman; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1987-07       Impact factor: 4.030

9.  Chlorimipramine--but not imipramine--rapidly reduces [3H]imipramine binding in human platelet membranes.

Authors:  E T Mellerup; P Plenge
Journal:  Eur J Pharmacol       Date:  1986-07-15       Impact factor: 4.432

10.  Dissociation kinetics of [3H]paroxetine binding to rat brain consistent with a single-site model of the antidepressant binding/5-hydroxytryptamine uptake site.

Authors:  J Marcusson; K Eriksson
Journal:  J Neurochem       Date:  1988-11       Impact factor: 5.372
View more
  1 in total

1.  Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization.

Authors:  S Ramamoorthy; A L Bauman; K R Moore; H Han; T Yang-Feng; A S Chang; V Ganapathy; R D Blakely
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.